Completed PHASE2 INTERVENTIONAL 2-arm NCT02043730

Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer. (GAP)

A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial

Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

Conditions Pancreatic Cancer Stage II

Interventions Gemcitabine Nab-paclitaxel and Gemcitabine

Updated 8 times since 2017 Last updated: Oct 7, 2019 Started: Jan 31, 2014 Primary completion: Mar 31, 2016 Completion: Jan 14, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pancreatic Cancer Stage II, this trial is completed. The trial is conducted by Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente and has accumulated 8 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jun 2018 — Nov 2019 [monthly]

Unknown Status PHASE2
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE2

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Istituto Nazionale Tumori di Napoli
Unità Sperimentazioni cliniche

Data source: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Bari, Italy , Benevento, Italy , Bergamo, Italy , Biella, Italy , Bolzano, Italy , Brescia, Italy , Busto Arsizio, Italy , Camposampiero, Italy , Como, Italy and 24 more locations